ARS Pharmaceuticals, Inc.
corporate_fare Company Profile
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for SPRY at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for SPRY spans 10-Q, 8-K, 10-K.
Recent high-impact activity:
- ARS Pharma 10-Q: Q3 Revenue $37.7M, Net Loss Narrows to $35.6M, $138.4M Cash
- ARS Pharma Q3 Revenue $37.7M, Net Loss Narrows to $35.6M; Breakeven Target Reaffirmed
- Q3 Revenue Climbs to $37.7M as Net Loss Narrows and SG&A Drops 42%
- ARS Pharmaceuticals Doubles Epinephrine Market Share as neffy Revenue Climbs
- ARS Pharmaceuticals Q2: Revenue Doubles, But Losses Widen and Legal Battles Mount
Financial Snapshot
Short Interest & Short Volume
11.09 days to coverFINRA reported short interest of 18,990,650 shares in SPRY as of the October 30, 2026 settlement, a 4.2% decrease from the prior period — about 11.1 days to cover at its recent average daily volume. On November 20, 2026, 67.3% of SPRY volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.